Related references
Note: Only part of the references are listed.Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
Jing Wang et al.
SUPPORTIVE CARE IN CANCER (2019)
Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers
Gunilla Huledal et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Inhibitory Effect of Single and Repeated Doses of Nilotinib on the Pharmacokinetics of CYP3A Substrate Midazolam
Hefei Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects
Hiroyuki Kusuhara et al.
DRUG METABOLISM AND DISPOSITION (2013)
Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
S. V. Vormfelde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin
N. Rao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
TD Bjornsson et al.
DRUG METABOLISM AND DISPOSITION (2003)
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
J Kirchheiner et al.
PHARMACOGENETICS (2002)
The effect of rifampin administration on the disposition of fexofenadine
MA Hamman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
